Latest Equity Incentives News

Clarity Pharmaceuticals reported a $64.3 million loss for FY2025 alongside significant clinical progress and a $203.6 million placement to fund its radiopharmaceutical pipeline expansion.

Wesfarmers Limited has announced a fully franked ordinary dividend of AUD 1.11 per share for the half-year ending June 2025, offering shareholders multiple currency payment options and a Dividend Reinvestment Plan.

humm Group has disclosed the key terms of CEO Angelo Demasi’s employment agreement, highlighting a $750,000 salary and significant incentive opportunities tied to company performance.

Stellar Resources has signed a non-binding Memorandum of Understanding to explore using the idle Avebury Nickel Mine plant for processing ore from its Heemskirk Tin Project, aiming to enhance production and reduce development costs.

BrainChip Holdings reports a significant revenue surge and reduced losses in H1 2025, underpinned by new contracts, strategic collaborations, and an expanded funding agreement.

Complii FinTech Solutions has posted a 28.7% increase in revenue for FY25 alongside a significant reduction in net loss, triggering the vesting of over 20 million performance rights.

Sarama Resources has secured A$2.7 million to advance exploration at its Cosmo and Mt Venn gold projects in Western Australia, while arbitration over its lost Burkina Faso permit progresses.

GBM Resources has appointed Daniel Hastings as its new CEO, bringing 25 years of global mining expertise to drive strategic growth and operational excellence.

Activeport Group Ltd reported a strong Q4 FY25 with significant revenue growth in software and Network as a Service segments, underpinned by new contracts with leading telecom providers and improved cash flow management.

Solara Minerals has strengthened its foothold in Western Australia’s gold and copper sector through a major project acquisition and key executive appointments, setting the stage for upcoming drilling campaigns.

TruScreen Group Limited has announced a placement of over 1.7 million shares to settle marketing invoices and provide an equity incentive to its CFO, signaling strategic capital management ahead of its next growth phase.

NeuroScientific Biopharmaceuticals has appointed Nathan Smith as CEO, leveraging his deep cell therapy expertise to accelerate clinical development and commercialisation of its StemSmart technology.